REDWOOD CITY, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Codexis CDXS will release its quarterly earnings report on Wednesday, 2025-08-13. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Codexis to report an earnings per ...

REDWOOD CITY, Calif., March 11, 2026 (GLOBE NEWSWIRE)-- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today ...

REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced ...

REDWOOD CITY, Calif. and JUPITER, Fla., June 01, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company and developer of high-performance enzymes, and Alphazyme ...

As of Sept. 30, institutional investors held over 86% of the outstanding shares. These include big names like BlackRock, Vanguard, and Fidelity as well as healthcare specialist funds including Vivo ...

REDWOOD CITY, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the appointments ...

Codexis has built its reputation on engineering enzymes for various applications, but its recent focus on the enzymatic manufacturing of siRNA therapies marks a significant evolution in its business ...

REDWOOD CITY, Calif. and BEVERLY, Mass.--(BUSINESS WIRE)--Codexis, Inc. (Nasdaq: CDXS) and seqWell, Inc. today announced the initiation of a strategic partnership and investment to accelerate the ...

Codexis Inc (NASDAQ:CDXS) intends to prioritize advancing and commercializing its Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis platform and its Pharmaceutical Manufacturing business. The company ...